Clinical Trials Logo

Carcinoma, Ductal clinical trials

View clinical trials related to Carcinoma, Ductal.

Filter by:

NCT ID: NCT02243007 Recruiting - Clinical trials for Resectable Pancreatic Cancer

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Start date: September 2014
Phase: Phase 2
Study type: Interventional

This research study is a Phase II clinical trial, which evaluates a combination of drugs, FOLFIRINOX and Gemcitabine/Nab-Paclitaxel, in the management of participants with resectable pancreatic cancer prior to surgery.

NCT ID: NCT01484704 Recruiting - Clinical trials for Mammary Ductal Carcinoma

The Significance of MRI in the Development of Diagnostics and Treatment of Breast Cancer

Start date: February 2011
Phase: N/A
Study type: Observational

The purpose of this study is to determine how MRI changes the treatment and diagnostics of ductal breast cancer. 100 women with newly diagnosed breast cancer will participate the study.

NCT ID: NCT01016002 Recruiting - Clinical trials for Non-curative Resectable Bile Duct Carcinoma

Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma

Start date: January 2006
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess efficacy and safety of Foscan (temoporfin) photodynamic therapy in the treatment of locally advanced perihilar bile duct carcinoma without distant metastases.

NCT ID: NCT00669747 Recruiting - Clinical trials for Ductal Carcinoma In Situ

Study Of Intraductal Carboplatin In Women With Ductal Carcinoma In Situ (DCIS)

Start date: May 2008
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to compare the safety of 100 mg carboplatin administered intraductally once on Day 1 or twice on Days 1 and 15 in women with ductal carcinoma in situ (DCIS) undergoing surgical management 2 to 4 weeks following the Day 15 intraductal infusion. Secondary objectives are to characterize the biologic and clinical effects with respect to: pharmacokinetics, extent of disease on MRI and mammogram, histopathological assessment of DCIS, and biomarker measurement of Ki-67, TUNEL and G-actin.